Infliximab and adalimumab (anti-TNF medicines)
The most widely used biologics for Crohn's: how they work, drips and injections, drug-level tests, side effects and pregnancy
In short
- Both block TNF-alpha, a protein that in excess damages the gut lining. Infliximab is given by drip (and later sometimes by injection); adalimumab is injected under the skin.
- Brands include Remicade, Remsima, Inflectra, Flixabi and Zessly (infliximab) and Humira, Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma (adalimumab).
- Some people make antibodies against the medicine. Blood tests of drug and antibody levels help your team adjust treatment, and adding azathioprine or methotrexate lowers the risk.
- NICE recommends them once standard treatments have not worked; the 2025 BSG guideline supports starting infliximab earlier for moderate to severe Crohn's.
- They raise the risk of infections. Avoid live vaccines, and tell your baby's health team if you took either in pregnancy.
Get help if
Call 999 or go to A&E
- You think you are having a severe allergic reaction, a stroke, a heart attack or a severe blistering skin reaction. The NHS says to call 999.
Urgent GP appointment or NHS 111
- You think you are having another serious side effect. The NHS says to call 111.
Contact your IBD team
- You have signs of infection, such as fever, a cough that will not go away, stinging when you pee or a hot, painful patch of skin. Crohn's & Colitis UK says to tell your IBD team immediately.
In an emergency call 999. For urgent advice call 111 or use 111 online. 123
On this page
What are they and how do they work?
Infliximab and adalimumab are biologic medicines: antibodies made by living cells in a laboratory. Both target a protein called tumour necrosis factor-alpha (TNF-alpha). Your body makes TNF-alpha to fight infection, but too much of it can damage the cells lining the gut, and this is thought to be part of what drives Crohn's. The medicines stick to TNF-alpha and block it, which lowers inflammation. That is why they are called anti-TNF medicines.23
Remicade was the first infliximab and Humira the first adalimumab. Other brands are biosimilars, which Crohn's & Colitis UK describes as very similar versions with the same treatment effect. The NHS lists Amgevita, Humira, Imraldi and Yuflyma among common adalimumab brands. You are prescribed a specific brand, and you may be moved between them.123
Who are they for?
Both are licensed for moderate to severe Crohn's in adults and children aged six or over. Crohn's & Colitis UK says they are often offered when steroids, azathioprine, mercaptopurine or methotrexate have not worked, have caused problems or are unsuitable. Infliximab is also used for active fistulas, and adalimumab may help some people when infliximab has not worked.23
NICE's 2010 appraisal, which is part of its Crohn's guideline, recommends infliximab or adalimumab for adults with severe active Crohn's that has not responded to, or cannot be treated with, standard treatment. It recommends infliximab for active fistulas and for severe Crohn's in children aged 6 to 17. NICE says treatment should be reviewed at least every 12 months, that a trial off treatment can be considered for people in stable remission, and that people who relapse should be able to restart.45
The 2025 BSG guideline goes further. Based partly on the UK PROFILE trial, where starting infliximab with an immunosuppressant soon after diagnosis led to more steroid-free and surgery-free remission, it says infliximab should be started early for moderate to severe Crohn's rather than only after other medicines fail. It also suggests infliximab, adalimumab or vedolizumab as first options for preventing Crohn's from returning after bowel surgery, whereas NICE's 2019 guideline says biologics should not be offered for that purpose after a complete resection.567
How are they given, and how well do they work?
Infliximab cannot be swallowed, because the gut would break it down. It is usually given through a drip into a vein (an infusion) in a hospital day unit. Crohn's & Colitis UK says an infusion takes one to two hours, and you should allow at least half a day for your first visit; later infusions are often quicker. Some hospitals offer adults the option of switching to injections under the skin at home after the first few infusions, which work as well.2
Adalimumab is always an injection under the skin, using a pre-filled pen or syringe, usually into the tummy or thigh. A nurse gives or supervises the first dose and trains you or a family member to do it at home. Adalimumab, and infliximab if you inject it, are usually delivered to your home by a specialist company and kept in the fridge. Your GP cannot prescribe them; they come from a hospital specialist.123
Some people feel better soon after starting. Crohn's & Colitis UK says infliximab may take two or three doses, and adalimumab may take up to 12 weeks for Crohn's. Your team will usually allow a few months before deciding whether it is working.23
In trials summarised by Crohn's & Colitis UK, about 40 in 100 people with moderate to severe Crohn's were in remission after a year of adalimumab, compared with 14 in 100 on placebo. For infliximab, more than twice as many people were in remission at one year as with placebo. Neither works for everyone.23
Why take them with azathioprine or methotrexate?
Over time some people's immune systems make antibodies against an anti-TNF medicine, which can stop it working. Taking an immunosuppressant such as azathioprine, mercaptopurine or methotrexate alongside it can lower this risk. In the SONIC trial, more people on infliximab plus azathioprine were in steroid-free remission at six months than on infliximab alone. Combining medicines brings its own risks: Crohn's & Colitis UK says taking azathioprine or mercaptopurine with infliximab can raise the risk of skin problems, and a rare lymphoma has been linked to these combinations (see side effects below).2389
The guidelines differ in tone here. NICE says the choice between a biologic alone and a combination should be discussed, explaining that it is uncertain which is better in the long run. The 2025 BSG guideline recommends that infliximab and adalimumab are started together with a thiopurine.56
What checks will I need?
Before starting, your team will check for infections that the medicine could make worse. This usually includes tuberculosis (TB), often with a chest X-ray, and blood tests for hepatitis and HIV. They will ask about heart problems, previous cancer, nerve conditions such as multiple sclerosis, chickenpox and shingles, travel and your vaccines.2310
During treatment you will have regular blood tests. The NHS mentions checks on the liver and kidneys for adalimumab. Your team may also measure how much of the medicine is in your blood and whether you have antibodies to it. The 2025 BSG guideline says these tests can guide raising the dose if the medicine is not working, or switching to a different medicine if antibody levels are high.1236
What side effects can they cause?
Common side effects listed by the NHS and Crohn's & Colitis UK include redness, itching or pain where you inject or have the drip, colds and sinus infections, headaches, tummy pain, feeling sick, skin rashes and muscle or joint pain. The NHS also lists mood changes, dizziness and blurred vision for adalimumab; do not drive if these affect you.123
The most important serious risk is infection. You may catch infections more easily, they may be more severe, and old infections such as TB or hepatitis B can come back. Rarer serious effects listed by the sources include severe allergic reactions, new or worse heart failure, liver problems, nerve damage, and a small increase in the risk of some skin cancers and lymphoma. A very rare lymphoma called HSTCL has been seen mainly in young men with Crohn's taking an anti-TNF together with azathioprine or mercaptopurine.123
You should be given a patient alert card to show to any doctor or dentist. Crohn's & Colitis UK also suggests good food hygiene, sun protection and keeping up with cervical screening.23
Vaccines, pregnancy and breastfeeding
Live vaccines should not be given while you take either medicine. Crohn's & Colitis UK says it may be safe about three months after your last dose, though you may be advised to wait longer. The yearly flu jab, COVID-19 and pneumococcal vaccines are not live and are recommended.23
Both medicines are generally considered safe in pregnancy, and stopping can risk a flare, which has its own dangers. They do cross the placenta later in pregnancy, so your team may suggest stopping partway through if your Crohn's is well controlled, or continuing if not. If you took either during pregnancy, your baby may need to wait for live vaccines such as rotavirus or BCG, so tell your baby's health team.123
Only small amounts get into breast milk and are likely to be broken down in the baby's gut, so both medicines can be used while breastfeeding. Studies have found normal growth and development in breastfed babies.123
Sources
This article is written in our own words from these sources. Each number in the text points to one of them.
- NHS Adalimumab Web page, Aug 2026 Read on the NHS website: Adalimumab
- Crohn's & Colitis UK Infliximab Guide, Jun 2024 Read on the Crohn's & Colitis UK website: Infliximab
- Crohn's & Colitis UK Adalimumab Guide, Sep 2024 Read on the Crohn's & Colitis UK website: Adalimumab
- NICE Infliximab and adalimumab for the treatment of Crohn's disease (TA187) Guideline, May 2010 Read on the NICE website: Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
- NICE Crohn's disease: management - Recommendations Guideline, May 2019 Read on the NICE website: Crohn's disease: management - Recommendations
- Frontline Gastroenterology (via PMC) Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease Guide, Nov 2025 Read the paper: Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease
- The Lancet Gastroenterology & Hepatology A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE) Study, May 2024 Read the paper: A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)
- New England Journal of Medicine Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC) Study, Apr 2010 Read the paper: Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)
- Crohn's & Colitis UK Methotrexate Guide, Mar 2023 Read on the Crohn's & Colitis UK website: Methotrexate
- Royal Free London NHS Foundation Trust Starting biologic medication Leaflet, Aug 2025 Read the Royal Free London NHS Foundation Trust leaflet: Starting biologic medication